Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis.
Sameem AbedinNahid RashidMark SchroederRizwan RomeeMary NauffalMuhamad Alhaj MoustafaMohamed A Kharfan-DabajaJeanne PalmerWilliam HoganMehrdad HefaziSamantha LarsonShernan HoltanZachariah DeFilippReena JayaniBhagirathbhai DholariaJoseph PidalaFarhad KhimaniMichael R GrunwaldCandace ButlerMehdi HamadaniPublished in: British journal of haematology (2021)
Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.